陝鼓動力(601369.SH):與陝煤集團榆林化學擬共設合資公司 投資後者相關項目
格隆匯 4 月 21日丨陝鼓動力(601369.SH)公佈,公司與陝煤集團榆林化學有限責任公司(“陝煤集團榆林化學”)擬共同成立合資公司,投資陝煤集團榆林化學1500萬噸/年煤炭分質清潔高效轉化示範項目烯烴、芳烴及深加工工程項目(“煤炭轉化項目”)配套10萬Nm3/h等級空分子項目(“10萬空分項目”)。
該項目投資將增加陝鼓動力100000Nm3/h運營規模,符合公司擴大氣體業務的發展戰略。同時,也可帶動公司“設備銷售、工程總包、工業服務”等產業,投資效益與協同效應明顯。該項目投資極大提高了陝鼓動力氣體運營市場影響力,對公司進軍大型空分領域具有重大示範意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.